Drug Profile
Research programme: anticancer antibodies - Takeda/CSIRO
Alternative Names: DX-2647; Human monoclonal antibody against IGF-II - Takeda/CSIROLatest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator CSIRO; Dyax
- Developer CSIRO; Shire
- Class Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 22 Jan 2016 Dyax has been acquired by and merged into Shire